EU says Moderna COVID vaccine production can continue after contamination incident

1 minute read

Vials of the Moderna COVID-19 vaccine are seen at Apotex pharmaceutical company as Humber River Hospital's mobile vaccine clinic vaccinate employees as part of the coronavirus disease (COVID-19) vaccination campaign, in Toronto, Ontario, Canada April 13, 2021. REUTERS/Carlos Osorio/File Photo

Register now for FREE unlimited access to Reuters.com

BRUSSELS, Aug 27 (Reuters) - Production of Moderna (MRNA.O) COVID-19 vaccines at a plant of partner Rovi (ROVI.MC) in Spain can continue after an initial assessment, the European Union drugs regulator said on Friday, as it continues its investigation of a contamination incident.

On Thursday Japan suspended the use of 1.63 million doses of the Moderna vaccine, with the company saying contamination could be due to a manufacturing issue on one of the production lines at its contract manufacturing site in Spain run by Rovi (ROVI.MC).

"COVID-19 vaccine production in Rovi is able to continue, following a preliminary risk assessment of the information received so far," the European Medicines Agency told Reuters in a statement on Friday.

"An investigation into the root cause is ongoing. EMA will be able to provide more information as the investigation progresses," it added.

Register now for FREE unlimited access to Reuters.com
Reporting by Francesco Guarascio @fraguarascio; Editing by Catherine Evans

Our Standards: The Thomson Reuters Trust Principles.